Loading
A third-generation EGFR pill used together with amivantamab as the first regimen to beat osimertinib in EGFR-mutant lung cancer.
Developed by Yuhan, licensed to Janssen. Approved August 2024 only in combination with amivantamab (MARIPOSA: PFS HR 0.70; OS HR 0.75 with median >12 months longer than osimertinib, 2025). Rash, paronychia, and venous thromboembolism (prophylactic anticoagulation for 4 months) are the combination's main burdens.
Irreversible mutant-selective EGFR TKI (exon 19 del, L858R, T790M), CNS-penetrant. Connects to EGFR.
1.Lazertinib slips into a pocket on EGFR.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Lazcluze is oral and Part D; its partner amivantamab is an infusion under Part B, so a patient on the MARIPOSA regimen pays under both benefits.
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA1122. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2024 | First-line EGFR exon 19 del / L858R NSCLC with amivantamab |
| EU | 2025 | 1L EGFR-mutant NSCLC with amivantamab; 20 Jan 2025 |
| England (NICE) | 2026 | Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with amivantamab · TA1122, published 21 January 2026, subject to the commercial arrangements for both drugs. |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Lazertinib" OR ABSTRACT:"Lazertinib" OR TITLE:"Lazcluze" OR ABSTRACT:"Lazcluze") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lazertinib, not a curated reading list.
Shares EGFR L858R, EGFR exon 19 deletion, Lung cancer drugs in England: what NICE has recommended, EGFR.
Shares EGFR exon 19 deletion & L858R, EGFR L858R, EGFR exon 19 deletion, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares Amivantamab + lazertinib (first-line EGFR NSCLC), Drug-tolerant persister cells, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares EGFR exon 19 deletion & L858R, EGFR L858R, EGFR exon 19 deletion, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares Amivantamab + lazertinib (first-line EGFR NSCLC), Amivantamab, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares EGFR L858R, EGFR exon 19 deletion, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, EGFR-mutated non-small-cell lung cancer, EGFR, Lung cancer (all types).
Shares EGFR L858R, EGFR exon 19 deletion, Non-small cell lung cancer (KEGG map), EGFR.